Gen AI Adoption And Pharma Cost Pressures Will Shape Steady Long Term Outcomes

Catalysts

About Indegene

Indegene provides technology and AI led services to global life sciences companies across commercial, medical, regulatory and safety operations.

What are the underlying business or industry changes driving this perspective?

• Although large pharma is currently leaning on partners like Indegene to centralize omnichannel and content operations, deeper adoption of AI led platforms at the enterprise level could be slower than management expects. This would cap the ramp of high value deals and temper revenue growth.
• Although Gen AI use cases in medical writing, pharmacovigilance and commercial content are expanding, clients may choose to in source more automation over time. This would pressure pricing on catalog and fixed price contracts and weigh on net margins.
• While the integration of BioPharm and other acquired capabilities is intended to broaden the commercial offering, any execution missteps or weaker than planned cross selling into Indegene’s base could limit revenue synergies and keep EBITDA margins below the 20% level for longer.
• Although life sciences companies are under clear pressure to improve efficiency and modernize go to market models, tighter cost control at large pharma could lead to more aggressive vendor consolidation and pricing negotiations. This would affect earnings growth even if volumes hold up.
• While the industry is steadily increasing its use of AI across the drug value chain, rising internal compliance, data security and regulatory scrutiny around AI in clinical, regulatory and safety workflows could slow deal conversion cycles and delay the revenue contribution from newer Gen AI platforms.

Assumptions

How have these above catalysts been quantified?

• This narrative explores a more pessimistic perspective on Indegene compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
• The bearish analysts are assuming Indegene's revenue will grow by 16.1% annually over the next 3 years.
• The bearish analysts assume that profit margins will increase from 13.5% today to 13.8% in 3 years time.
• The bearish analysts expect earnings to reach ₹7.1 billion (and earnings per share of ₹28.43) by about April 2029, up from ₹4.4 billion today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as ₹8.2 billion.
• In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 24.5x on those 2029 earnings, down from 25.8x today. This future PE is lower than the current PE for the IN Life Sciences industry at 28.1x.
• The bearish analysts expect the number of shares outstanding to decline by 0.06% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 13.8%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Large pharma customers are described as returning to the table with shorter decision cycles and a strong appetite for Gen AI led omnichannel and medical solutions. This could support higher enterprise level spending with Indegene over time and lift revenue and earnings.
• Management highlights multiple large new contracts, including engagements with expected annual revenues of over US$10m and US$5m from FY 2027, along with a growing set of $1m plus accounts and US$70,000 plus revenue per employee. This could underpin sustained business expansion and support margin resilience.
• The life sciences sector is described as resilient with a 5% to 8% CAGR outlook to 2029 and rising pressures to improve efficiency, centralize operations and adopt AI. This could create a long running demand tailwind for Indegene’s commercial, medical, regulatory and safety offerings and support revenue growth.
• Management is already investing around 1.8% of revenue in Gen AI capabilities and expects EBITDA margins to move back toward 20% over 6 to 8 quarters while acquisition related amortization tapers after FY 2027. Together, these factors could support higher net margins and earnings.
• Cash generation is described as strong, with operating cash flow to PAT at about 154% and cash flow to adjusted EBITDA near 90%, while BioPharm integration synergies and M&A costs are expected to improve PAT and EPS. This could provide balance sheet and earnings support that is inconsistent with a flat share price view.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bearish price target for Indegene is ₹490.0, which represents up to two standard deviations below the consensus price target of ₹587.29. This valuation is based on what can be assumed as the expectations of Indegene's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of ₹690.0, and the most bearish reporting a price target of just ₹490.0.
• In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be ₹51.0 billion, earnings will come to ₹7.1 billion, and it would be trading on a PE ratio of 24.5x, assuming you use a discount rate of 13.8%.
• Given the current share price of ₹472.6, the analyst price target of ₹490.0 is 3.6% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.